Stock Analiz

Elutia Inc. ELUT

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026

$0.82Market cap $36M
Open the interactive analysis →

Elutia Inc. (ELUT) is a healthcare company listed in the US with a market value of about $36M. In the twelve months to September 30, 2026 it had revenue of $17M and net income of $54M, a net margin of 320.6%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is value (2/5); the weakest is shareholder returns (0/5).

Key numbers: a P/E of 0.7, a 5-year average ROIC of -89%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 80% below the current price.

About Elutia

Elutia is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. Revenue went from $43M in 2019 to $14M in 2024, a decline of about 19.5% a year. It was profitable in 1 of the last 7 years in our data. Its share count rose by 232% over three years (dilution for shareholders).

Score: 1.2 / 5

Value2/5
Future growth1/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)0.7
Forward P/E—
P/FCF—
P/S2.1
P/B2.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-139.2%
Shareholder yield0.0%
Intrinsic value vs. price−80%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-178.9%
ROIC (5-yr avg.)-89.0%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$17M—$14M$25M$24M$47M$43M$43M
Net income$54M$53M-$54M-$38M-$33M-$25M-$22M-$12M
Free cash flow-$51M-$47M-$23M-$22M-$22M-$16M-$14M-$8M
EPS (diluted)$1.15$0.87$-1.86$-2.07$-2.38$-2.38$-8.88$-18.48
Net margin320.6%—-372.9%-152.2%-137.9%-52.4%-51.1%-27.8%
ROIC—-67.2%——-142.9%-56.9%-23.9%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Elutia’s P/E ratio?

About 0.7, based on the last twelve months of diluted earnings per share.

Is Elutia stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 80% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Elutia pay a dividend?

Not currently.

Is Elutia a good stock to buy?

We do not give buy or sell advice. Elutia scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.